We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Lancet and the New England Journal of Medicine (NEJM) yesterday retracted separate studies of two different COVID-19 treatments because of concerns over the underlying data provided by the same data analytics company, Surgisphere. Read More
Researchers in the UK are launching a clinical trial to test a unique formulation of ibuprofen for treatment of severe acute respiratory distress syndrome (ARDS) in COVID-19 patients. Read More
Several common cardiovascular drugs are being studied as potential COVID-19 treatments, with early findings suggesting they pose no increased risks for patients taking them regularly. Read More
The London study will recruit hospitalized COVID-19 patients who will either receive the standard of care or ibuprofen in addition to standard of care. Read More
Two respected medical journals have raised questions about the reliability of data provided by a controversial data analytics company in two different trials done for two COVID-19 treatments. Read More
The University of Minnesota has published results from its COVID-19 hydroxychloroquine trial that show the anti-malaria drug is ineffective at preventing coronavirus infection, echoing negative results from other recent studies. Read More
BerGenBio has announced that the first COVID-19 patient was dosed with bemcentinib in a phase 2 trial to evaluate the drug as a potential treatment. Read More